Abstract:
The present invention is directed to a compound represented by Structural Formula I: wherein the variables are described herein. Also included are methods of making the compounds of Structural Formula (I) and methods of using the compounds as antioxidants.
Abstract:
The invention relates to the use of a renin inhibitor, or a pharmaceutically acceptable salt thereof, alone or in combination with one or more active ingredient, for the manufacture of a medicament for the treatment of diabetic cardiomyopathy.
Abstract:
A silicon carbide semiconductor device includes a substrate and a junction field effect transistor. The transistor includes: a first semiconductor layer disposed on the substrate; a first gate layer disposed on a surface of the first semiconductor layer; a first channel layer adjacent to the first gate layer on the substrate; a first source layer connecting to the first channel layer electrically; a second gate layer adjacent to the first channel layer to sandwich the first channel layer; a second channel layer adjacent to the second gate layer to sandwich the second gate layer; a third gate layer adjacent to the second channel layer to sandwich the second channel layer; and a second source layer connecting to the second channel layer electrically.
Abstract:
Disclosed are, inter alia, methods, apparatus, data structures, computer-readable media, mechanisms, and means for establishing a call across a network. For example, the network may include a first edge switch, a second edge switch, and an ATM core network coupled to the first and the second edge switches and configured to allow the second edge switch to communicate with the first edge switch. The second edge switch, being responsive to a received Q.2630.1 AAL2 message, is configured to send a first Private Network-Network Interface (PNNI) setup message to the first edge switch as part of establishing a call between or through one or more of the first and the second edge switches.
Abstract:
Methods and apparatus are disclosed for changing the bandwidth or other traffic characteristic of an established packet call in response to an identification of the requirements of the call. In response to the detection of a type of call, such as a fax or modem call, ATM signaling is performed with peer signaling agent(s) located in the ATM network to increase the bandwidth of an already established portion of a call through the ATM network. This signaling typically includes sending a call modify request message and receiving a modify acknowledgement message, with these messages typically, but not limited to, conforming with a Q.2963 signaling standard.
Abstract:
This invention relates to compositions for the sustained release of biologically active polypeptides, and methods of forming and using said compositions, for the sustained release of biologically active polypeptides. The sustained release compositions of this invention comprise a biocompatible polymer having dispersed therein, a biologically active polypeptide and a sugar.
Abstract:
In general, in one aspect, the disclosure describes a semiconductor device that includes a functional circuit and a dc-to-dc power converter. The power converter converts, regulates, and filters a DC input voltage to produce a DC output voltage and provides the DC output voltage to the functional circuit. The dc-to-dc power converter has an operating frequency above 10 MHz.
Abstract:
The present invention is directed to a compound represented by Structural Formula I: wherein the variables are described herein. Also included are methods of making the compounds of Structural Formula (I) and methods of using the compounds as antioxidants.
Abstract:
An embodiment may include an apparatus comprising a dejitter buffer to receive packets containing audio data, a codec coupled with the dejitter buffer, the codec to receive coded audio frames from the dejitter buffer and decode them, and a concealed seconds meter coupled with the dejitter buffer, the concealed seconds meter to record concealment events by the decoder to provide an objective measure of media impairment. Another exemplary embodiment may be a method comprising receiving packets containing audio information at a dejitter buffer, decomposing the packets to coded audio frames, sending the coded audio frames to a decoder and decoding the frames, generating a concealment output stream if the decoder does not receive a valid frame from the dejitter buffer, and recording concealment events to provide an objective measure of media impairment.
Abstract:
The present invention provides polynucleotides encoding clot-specific streptokinase proteins possessing altered plasminogen characteristics, including enhanced fibrin selectivity. The kinetics of plasminogen activation by these proteins are distinct from those of natural streptokinase, in that there is a temporary delay or lag in the initial rate of catalytic conversion of plasminogen to plasmin. Also disclosed are processes for preparing the proteins.